Sanwa and Kowa's DPP-4 licensing deal goes global
This article was originally published in Scrip
Executive Summary
Sanwa Kagaku Kenkyushohas granted fellow Japanese firm Kowaexclusive development and marketing rights to its antidiabetic DPP-4 inhibitor, SK-0403, in all markets worldwide excluding South Korea, China and Taiwan. The agreement extends an August co-development and co-commercialisation alliance for Japan, where SK-0403 is in Phase II trials. Sanwa will receive undisclosed upfront, milestone and royalty payments. Kowa recently extended its US marketing capability through the acquisition of ProEthic Pharmaceuticals in August (Scrip Online, August 5th, 2008).
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: another big deal in radiopharmaceuticals; BioNTech’s ADC pipeline; China CDMOs embrace uncertain future; at look at the rivals in MASH; and industry views on how AI might be transformative.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Galderma prepares to take on Dupixent; Pfizer’s plans for Adcetris in DLBCL; Lilly’s donanemab approval delayed again; the psychedelic R&D pipeline; and an interview with BMS’s CDTO Greg Meyers.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Bayer won’t split, for now; Pfizer’s next-gen ADC pipeline; oncology dominates investment but other areas grow; goodbye NASH, hello MASH; and BMS’s CEO gives his views on India.